BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that three abstracts related to the company’s development program for GATTEX™ (teduglutide) for intestinal failure associated with short bowel syndrome (SBS) were accepted for presentation at the 2008 Digestive Disease Week (DDW) conference in San Diego May 17-22, 2008. The results from a Phase 3 study of GATTEX for SBS patients who are dependent upon parenteral nutrition will be presented in an American Gastroenterological Association (AGA) Institute clinical science plenary session. A second oral presentation will review improvements in fluid balance in the Phase 3 SBS study in an AGA Institute SBS research forum. The date, time, and location for the two oral sessions, as well as for a poster presentation are listed below.
